They reported localization of the protein kinase inhibitor vemurafenib within tumor regions of human malignant melanoma, where it specifically bound to its targets, BRAF mutated proteins, as opposed to BRAF negative tumor regions. This evidence concerns the gene WEE1 and neoplasm.